• FDA approves Karyopharm’s multiple myeloma drug Xpovio pharmaceutical-technology
    July 05, 2019
    The US Food and Drug Administration (FDA) has awarded accelerated approval to Karyopharm Therapeutics’ Xpovio (selinexor) to treat relapsed or refractory multiple myeloma (RRMM) in adults.
PharmaSources Customer Service